Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval
- ISBN-10
- 1461581524
- ISBN-13
- 9781461581529
- Category
- Medical
- Pages
- 311
- Language
- English
- Published
- 2013-11-11
- Publisher
- Springer Science & Business Media
- Author
- Beverly A. Teicher
Description
Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
Get the book
Other editions
-
- 2004-02-01
- 451 pages
- Ebook
- Springer Science & Business Media
-
- 2004-02-01
- 451 pages
- Paperback
- Humana
Similar books
-
Anticancer Drug Development Guide
By Beverly A. TeicherAnticancer Drug Development Guide
-
Principles of Anticancer Drug Development
By Elizabeth Garrett-Mayer, Manuel Hidalgo, S. Gail Eckhardt15.4.1.4 Determinants of Response to RTKTherapy Molecular determinants of TKI-based therapy may be different than that of monoclonal antibodies. EGFR mutations appear to determine the clinical efficacy of tyrosine kinase inhibitors.
-
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
By William D. Figg, Howard L. McLeodJ Clin Oncol 2003; 21:1967–1972. Physicians' Desk Reference, 57th Edit. Eloxatin (oxaliplatin for injection). Medical Economics/ Thomson PDR, 2003, pp. 2999–3003. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML.
-
New Approaches to Natural Anticancer Drugs
By Soodabeh SaeidniaThis book provides an up-to-date review of recently identified natural anti-tumor compounds from various natural origins including plants, fungi, endophytic fungi and marine organisms.
-
Anticancer Drug Development
By David J. Kerr, Bruce C. BaguleyContaining concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell ...
-
Cancer Therapeutics: Experimental and Clinical Agents
By Beverly A. TeicherCancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators...
-
In Vitro Bioassay Techniques for Anticancer Drug Discovery and Development
By Dhanya Sunil, Raghu Chandrashekhar H, Pooja KamathKey Features, Provides a user-friendly, one-stop, comprehensive and coherent foundation for in vitro anticancer drug development, An essential guide to young investigators starting a program on natural resources in the anticancer area from ...
-
Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs
By MD, PhD, Ashkan EmadiFrom traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents, this book covers the staggering advances in cancer pharmacology that are propelling new standards of care for common and uncommon ...
-
Phase I Oncology Drug Development
By Timothy A. Yap, Jordi Rodon, David S. HongThis book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials.
-
The Drug Development Paradigm in Oncology: Proceedings of a Workshop
By Board on Health Care Services, Health and Medicine Division, EngineeringBOX 5 Lung Cancer Master Protocol Trial Mary Redman, associate member of the Clinical Research Division at the Fred Hutchinson ... the Foundation for the National Institutes of Health (FNIH), a number of patient advocacy organizations, ...